Gilead Sciences

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Simplify's Rating
Why Gilead Sciences is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Total Funding

$15.9B

Headquarters

Foster City, California

Founded

1987

Overview

Company Historically Provides H1B Sponsorship

Gilead Sciences focuses on discovering, developing, and commercializing medicines to meet medical needs in areas like HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its supply chain and product offerings. The company's goal is to improve health equity and access to care globally, exemplified by initiatives like the COMPASS Initiative and HepConnect, aimed at removing barriers to healthcare and ensuring its medicines reach those in need.

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead's manufacturing efficiencies strengthen its CAR-T cell therapy production capabilities.
  • The STAT6 partnership with LEO Pharma offers potential in treating inflammatory diseases.
  • Investment in Xilio Therapeutics supports advancements in tumor-activated immuno-oncology therapies.

What critics are saying

  • Increased competition in HIV treatments may impact Gilead's market share.
  • Potential regulatory hurdles could delay the STAT6 program's development.
  • Patent expirations of key drugs could lead to revenue losses.

What makes Gilead Sciences unique

  • Gilead's lenacapavir is a breakthrough in HIV care, enhancing its market leadership.
  • Strategic partnerships, like with LEO Pharma, bolster Gilead's inflammation research portfolio.
  • Gilead's collaboration with Tubulis expands its oncology offerings with innovative ADCs.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$15873.6M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

BioProcess International
Jan 17th, 2025
Gilead cites manufacturing efficiencies as CAR-T advantage in 2025

At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company's manufacturing infrastructure as one of its key advantages in cell therapy production.

PharmiWeb
Jan 13th, 2025
Gilead And Leo Pharma Enter Into Strategic Partnership To Accelerate Development Of Oral Stat6 Program With Potential In Multiple Inflammatory Diseases

-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders ---- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. ---- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology --FOSTER CITY, Calif and BALLERUP, Denmark, January 11, 2025 – Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signaling, which are clinically validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis, asthma, and COPD, amongst many others. Targeting STAT6 has shown potential preclinically to treat a broad population of patients and provide an oral alternative to those currently treated with injectable biologics.Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.“As we continue to expand our inflammation portfolio, we're committed to developing next-generation therapies to support long-term remission in patients with inflammatory diseases through mechanisms that block major pathogenic pathways, eliminate pathogenic cells, tolerize the immune system, and restore cell function,” said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. “By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions.”“STAT6 holds potential for treating various inflammatory diseases, including outside dermatology

Dermatology Times
Jan 13th, 2025
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases

Last week, LEO Pharma announced a strategic partnership with biopharmaceutical company, Gilead Sciences, Inc. to develop programs for their STAT6 (signal transducer and activator of transcription 6).

Fee Only News
Jan 11th, 2025
Gilead, LEO Pharma partner to develop programs for inflammatory diseases By Reuters

(Reuters) - Gilead Sciences (NASDAQ:) said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

Indian Mirror
Dec 30th, 2024
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care

The development of lenacapavir by Gilead Sciences has been described by the journal Science as the 2024 Breakthrough of the Year.

Recently Posted Jobs

Sign up to get curated job recommendations

Gilead Sciences is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Gilead Sciences's jobs every 8 hours, so check again soon! Browse all jobs →